Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Bevacizumab-alone Maintenance Treatment Progression
Interventions: DRUG: Durvalumab|DRUG: Bevacizumab
Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
Collaborators: Fundacion CRIS de Investigación para Vencer el Cáncer